Results 61 to 70 of about 1,072 (154)

Cell-Free Mitochondrial DNA in Cell Culture Supernatant: Fragment Size Analysis and FBS Contamination Assessment

DNA
Background/Objectives: Circulating cell-free DNA (cfDNA) consists of genomic DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) fragments released from cells primarily through apoptosis and necrosis.
Patrizia Cesare, Sabrina Colafarina, Antonella Bonfigli, Anna Rita Volpe, Massimo Aloisi, Osvaldo Zarivi, Anna Maria Giuseppina Poma   +6 more
doaj   +1 more source

Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids

Human Genomics, 2023
Background Fragmentomics, the investigation of fragmentation patterns of cell-free DNA (cfDNA), has emerged as a promising strategy for the early detection of multiple cancers in the field of liquid biopsy.
Jaeryuk Kim, Seung-Pyo Hong, Seyoon Lee, Woochan Lee, Dakyung Lee, Rokhyun Kim, Young Jun Park, Sungji Moon, Kyunghyuk Park, Bukyoung Cha, Jong-Il Kim   +10 more
doaj   +1 more source

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Molecular Cancer, 2022
Early detection can benefit cancer patients with more effective treatments and better prognosis, but existing early screening tests are limited, especially for multi-cancer detection.
Hua Bao, Zheng Wang, Xiaoji Ma, Wei Guo, Xiangyu Zhang, Wanxiangfu Tang, Xin Chen, Xinyu Wang, Yikuan Chen, Shaobo Mo, Naixin Liang, Qianli Ma, Shuyu Wu, Xiuxiu Xu, Shuang Chang, Yulin Wei, Xian Zhang, Hairong Bao, Rui Liu, Shanshan Yang, Ya Jiang, Xue Wu, Yaqi Li, Long Zhang, Fengwei Tan, Qi Xue, Fangqi Liu, Sanjun Cai, Shugeng Gao, Junjie Peng, Jian Zhou, Yang Shao   +31 more
doaj   +1 more source

Circulating Mitochondrial DNA Measures Across Malignancies: Diagnostic Accuracy and Prognostic Associations

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Circulating mitochondrial DNA is being investigated as a liquid‐biopsy biomarker because of its high copy number and release during cellular stress. However, diagnostic estimates vary across tumor types and assays, and prognostic studies have measured both cell‐free mtDNA and cellular blood‐derived mtDNA, which are not analytically ...
Ziying Zhang, Ying Jiang, Yu Gong, Hui Xie, Yaqian Han, Peng Chen   +5 more
wiley   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

First-trimester multi-modal cell-free DNA analysis for prediction of preterm and term preeclampsia

AJOG Global Reports
BACKGROUND: Preeclampsia, which is a leading cause of maternal and perinatal mortality and morbidity, represents a biologically heterogeneous syndrome. First-trimester screening with the Fetal Medicine Foundation (FMF) competing-risks model for preterm ...
Rebecca Ertl, MD, Argyro Syngelaki, PhD, Olga Frank, PhD, Lukas Lüftinger, PhD, Eva Lukáčová, PhD, Casper Lumby, PhD, Adrian Stütz, PhD, Stephan Beisken, PhD, Andreas E. Posch, PhD, Kypros H. Nicolaides, MD   +9 more
doaj   +1 more source

An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT Antibodies to Epstein‐Barr virus (EBV) proteins can predict nasopharyngeal carcinoma (NPC) risk. We previously defined a prototype EBNA1 protein panel and multiplex immunoblot assay that distinguishes NPC risk several years pre‐diagnosis.
Benjamin E. Warner, Japan Patel, Rebecca Satterwhite, Renwei Wang, Jennifer Adams‐Haduch, Woon‐Puay Koh, Jian‐Min Yuan, Kathy H. Y. Shair   +7 more
wiley   +1 more source

Cell‐Free DNA Analysis: Simpler Assays or Richer Information?

Medicine Bulletin, Volume 2, Issue 4, Page 347-349, September 2026.
Hengrui Liu
wiley   +1 more source

Watch and Wait Strategy for Locally Advanced Rectal Cancer: Update From Results of Recent Clinical Trials

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Locally advanced rectal cancer (LARC) is a common malignant tumor in the digestive system. Currently, despite growing recognition of personalized medicine, systematic risk stratification and full incorporation of patient preferences for anal preservation and treatment tolerance remain challenging in some clinical settings.
Ruocheng Yin, Zhigang Chen, Xinliang Liu, Dan Zong, Xia He   +4 more
wiley   +1 more source

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach ...
Katherine Antel, Nina Xiong, Mwanasha Merrill, Taiyang Chen, Lauren McGrath, Clara Droessler, Maxine van der Schyff, Meng‐Xuan Wu, Dylan Cheddie, Charlotte Slome, Liam McBride, Jonathan Day, Zainab Mohamed, Nazia Fakie, Nomonde Mbatani, Charlotte Shultz, Graeme Meintjes, Svitlana Tyekucheva, Elizabeth F. Cohen, Michael Y. Tolstorukov, Estelle Verburgh, Mark A. Murakami   +21 more
wiley   +1 more source